Kemal Malik - 02 Jan 2026 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role
Director
Signature
/s/ Matthew Bartholomae, Attorney-in-fact for Kemal Malik
Issuer symbol
RNAC
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
06 Jan 2026, 16:19:14 UTC
Previous filing
06 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Malik Kemal Director C/O CARTESIAN THERAPEUTICS, INC., 7495 NEW HORIZON WAY, FREDERICK /s/ Matthew Bartholomae, Attorney-in-fact for Kemal Malik 06 Jan 2026 0001797921

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Award $0 +2,600 +30% $0.000000 11,133 02 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNAC Stock Option (Right to Buy) Award $0 +7,800 $0.000000 7,800 02 Jan 2026 Common Stock 7,800 $6.76 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.